Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A
Lancet Oncol. 2014 15 (3): 323-32

PMID: 24508103 · PMCID: PMC4382632 · DOI:10.1016/S1470-2045(14)70012-9

MeSH Terms (16)

Adult Aged Dacarbazine Disease-Free Survival Female Follow-Up Studies Humans Indoles Male Melanoma Middle Aged Mutation Protein Kinase Inhibitors Proto-Oncogene Proteins B-raf Sulfonamides Vemurafenib

Connections (1)

This publication is referenced by other Labnodes entities: